AAIPharma Services Corporation (AAI) / Cambridge Major Laboratories, Inc. (CML), a provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, has launched a new brand and identity as a Alcami.

Originally joined together in late 2013, AAI and CML combined to offer analytical testing and development services for active pharmaceutical ingredients (APIs) with oral solid and parenteral dose finished product capacity. Providing an integrated offering for both drug substance and drug product at every development stage beginning with solid state chemistry and formulation development, Alcami is the new name for the integrated outsourcing offering.

Alcami recently announced investments in additional capabilities and capacity for oral solid dose manufacturing and parenteral fill-finish capabilities and capacity, including additional sterile lines and lyophilization capacity. Additionally, Alcami will be relocating its current St. Louis Analytical Testing Services to facility at the Cortex Innovation Center in St. Louis, Missouri, which provides analytical testing solutions for manufacturers' new drug entities, generic drugs, animal health products, medicated consumer health products, chemicals and biopharmaceuticals.

Source: Alcami